The incidence of injection site reactions with By dur eon is about 20%, which is much higher than any other GLP analogYour skin better be dur able
(2024) 5:e651
Thats exactly who should be getting this therapy. Targeting Alstrm Syndrome In Effectiveness of the Dual GIP/GLP1-Agonist Tirzepatide in 2 Cases of Alstrm Syndrome, a Rare Obesity Syndrome , published in JCEM in April, Thomas Scherer, MD, of the Medical University of Vienna, in Vienna, Austria, and team showed tirzepatides efficacy even in the particularly difficult-to-treat Alstrm syndrome (AS), a rare, genetic, multisystemic disorder, characterized by, among other conditions, diabetes with profound insulin resistance due to marked hyperphagia
Vildagliptin does not have a dedicated CVOT, however, in the VIVIDD study, an increase in end systolic and diastolic volumes was noted [67]